Kevzara
| Chemical Name | sarilumab |
| Dosage Form | Injection (subcutaneous; 150 mg/1.14 mL, 200 mg/1.14 mL) |
| Drug Class | Monoclonal antibodies |
| System | Musculoskeletal |
| Company | Sanofi-Aventis |
| Approval Year | 2017 |
Indication
- For treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs